Allogene Therapeutics
Pete Sabin has a strong background in facilities and engineering, with their most recent role at Allogene Therapeutics as the Director of Facilities and Engineering. Prior to this, they held the position of Associate Director Facilities and Engineering at the same company. Before their time at Allogene Therapeutics, Pete served as the Director of Project Management at Automated Engineering Services, Inc. and as the Director of Engineering at Delta Project Management. Pete also worked as a Consultant/Principal at Straight Line Consulting for ten years. Pete's career began at PaineWebber, Inc. where they served as a Vice President, handling mortgage origination services and managing repurchase trades for the whole loan repo desk.
Pete Sabin's education history includes a Bachelor of Science (BSc) in Economics from the University of Florida, which they obtained between the years 1986 and 1991. Pete then pursued a Master of Science (MSc) in Ocean Engineering from the Massachusetts Institute of Technology, specializing in the Department of Mechanical Engineering, from 1999 to 2001. Additionally, they engaged in post baccalaureate studies at both Columbia University and Fordham University in the year 1997. However, the specific degrees obtained during these post baccalaureate studies are not mentioned.
This person is not in the org chart
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.